ncRNA basic information
ncRNA ID:
MI0000802
ncRNA Database:
miRBase
ncRNA Name:
miR-340
ncRNA Type:
miRNA
ncRNA Expression:
down-regulated
ncRNA Method:
PCR
ncRNA Target Gene:
ZEB1
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The purpose of this study was to elucidate the role of miR-340 in chemoresistance of OS. Plasmid construction and transfection, miRNA arrays, PCR analyses, and western blot analysis, as well as MTT, apoptosis, and luciferase assays were carried out in MG-63 cells and MG-63/cisplatin (DDP)-resistant cells. The results showed that miR-340 was downregulated in OS tissues and drug-resistant OS cells. Moreover, a negative correlation was observed between miR-340 and ZEB1 expression in OS tissues. Forced expression of miR-340 in drug-resistant OS cells significantly reduced multidrug resistance-1 and P-gp expression. Overexpression of miR-340 enhanced sensitivity to DDP by inhibiting viability and promoting apoptosis. The luciferase assay and western blot analysis identified ZEB1 as a direct target of miR-340, and miR-340 negatively regulated ZEB1 expression. Ectopic expression of ZEB1 reversed the effects of miR-340 on P-gp expression, cell viability, and apoptosis. miR-340 alleviated chemoresistance of OS cells by targeting ZEB1. Our results indicate that targeting miR-340 may be a potential therapeutic approach to treat drug-resistant OS.
Drug Response:
resistant
Cancer basic information
Cancer:
osteosarcoma
Tissue/Cell:
tissue and cell line (MG-63,d MG-63/DDP )
Other information
Title:
miR-340 alleviates chemoresistance of osteosarcoma cells by targeting ZEB1.
Journal:
Anticancer Drugs
Published:
2018
PubMed ID:
29494357